Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
47High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05088356CT.gov Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft | — | Active Not Recruiting | — | — | — |
NCT02991898CT.gov Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | — | Terminated | — | — | — |
NCT01660607CT.gov Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell | — | Completed | — | — | — |
NCT01050764CT.gov Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chronic Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Treg Cells (this asset) | Masonic Cancer Center, University of Minnesota | P2 | B · 60 |
| Cyclophosphamide | City of Hope Medical Center | P3 | BBB |
| Nilotinib | Novartis Pharmaceuticals | P4 | BBB |
| Therapeutic Allogeneic Lymphocytes | University of Chicago | P2 | BBB |
| Sargramostim | Virginia Commonwealth University | P2 | BBB |
| Romidepsin | Center for International Blood and Marrow Transplant Research | P2 | BBB |
| Alemtuzumab | Diane George | P2/3 | BB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BB |
| Imatinib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Chronic Myeloid Leukemia cohort
Other indications for Treg Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myeloproliferative Neoplasm | — | P2 | B · 62 |
| Acute Lymphoblastic Leukemia | — | P2 | B · 58 |
| Marginal Zone Lymphoma | — | P2 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Treg Cells in Chronic Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/treg-cells-chronic-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →